• Explore /
  • Poster
  • / Margetuximab (M) plus pembrolizumab (P) in ERBB2-amplified PD-L1+ gastroesophageal adenocarcinoma (GEA) post trastuzumab (T).

Margetuximab (M) plus pembrolizumab (P) in ERBB2-amplified PD-L1+ gastroesophageal adenocarcinoma (GEA) post trastuzumab (T).

Abstract Poster

Authors

Daniel Catenacci

Daniel V.T. Catenacci

University of Chicago Pritzker School of Medicine, Chicago, IL

Daniel V.T. Catenacci , Haeseong Park , Hope Elizabeth Uronis , Yoon-Koo Kang , Jill Lacy , Peter C. Enzinger , Se Hoon Park , Keun Wook Lee , Matthew C.H. Ng , Philip Jordan Gold , Jennifer Yen , Aleksandra Franovic , Ronan Joseph Kelly , Aisha Wynter-Horton , Daner Li , John Muth , Jan E. Baughman , Sam Hong , Jan Kenneth Davidson-Moncada , Yung-Jue Bang

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2018 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Gastrointestinal (Noncolorectal) Cancer

Track

Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Sub Track

Esophageal or Gastric Cancer

Clinical Trial Registration Number

NCT02689284

Citation

J Clin Oncol 36, 2018 (suppl; abstr 4030)

DOI

10.1200/JCO.2018.36.15_suppl.4030

Abstract #

4030

Poster Bd #

219

Abstract Disclosures

Similar Posters

First Author: Daniel V.T. Catenacci

First Author: Daniel V.T. Catenacci

First Author: Timothy Jay Price

First Author: Daniel V.T. Catenacci